EU/3/20/2306: Orphan designation for the prevention of bronchopulmonary dysplasia

Retinol palmitate


On 27 July 2020, orphan designation EU/3/20/2306 was granted by the European Commission to Provepharm S.A.S, France, for retinol palmitate for the prevention of bronchopulmonary dysplasia.

Key facts

Active substance
Retinol palmitate
Intended use
Prevention of bronchopulmonary dysplasia
Orphan designation status
EU designation number
Date of designation

Provepharm S.A.S.
22 Rue Marc Donadille
13013 Marseille
Tel: +33 4 91 08 69 30

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating